2022 |
|---|
May 04, 2022
FDA Approves Orphalan's CUVRIOR™ (trientine tetrahydrochloride), the first treatment for Wilson's disease in over five decades Brand Institute is proud to announce working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the United States Food and Drug Administration on April 28, 2022. |
|
Apr 18, 2022
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed. |
|
Apr 25, 2022
FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc. Brand Institute is proud to announce working with Lipocine Inc. in developing the brand name TLANDO®, approved by the Food and Drug Administration (FDA) on March 28, 2022. |
|
Apr 19, 2022
Fernando González Díaz to Design Brand Institute's New Corporate Office in Puerto Rico As Brand Institute expands its operations in San Juan, Puerto Rico, it is proud to announce that it has enlisted Fernando González Díaz, Founder & Principal of Urban Venture Group (UVG), to design the company's new corporate office located at the Ritz-Carlton Reserve Dorado Beach Resort |
|
Apr 18, 2022
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed. |
Mar 28, 2022
Oasmia announces completion of name change to Vivesto Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, announces that as of today, 28 March, its new name, Vivesto AB, has been registered with the Swedish Companies Registration Office. |
|
Feb 22, 2022
Maxim Biomedical's ClearDetect™ COVID-19 Antigen Home Test Receives Emergency Use Authorization (EUA) from the U.S. FDA Brand Institute is proud to announce its successful partnership with Maxim Biomedical (MaximBio) in naming their MaximBio ClearDetect™ COVID-19 Antigen Home Test. |
|
Feb 3, 2022
Carlos Beltrán Baseball Academy (CBBA) Partners with Global Naming Agency Brand Institute Brand Institute is proud to announce its support and enthusiastic patronage of the Carlos Beltrán Baseball Academy (CBBA), a prestigious high school in Florida, Puerto Rico, that specializes in teaching baseball, academics, and the personal development of their students. |
|
Feb 1, 2022
FDA Approves SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Moderna in naming their FDA-approved COVID-19 vaccine: SPIKEVAX®, the second COVID-19 vaccine to be fully approved by the regulatory agency. |
|
Jan 24, 2022
Brand Institute Appoints William (Bill) Johnson to Co-Chief Executive Officer & President Brand Institute is pleased to announce the appointment of William (Bill) Johnson to the role of Co-Chief Executive Officer and President. Mr. Johnson is a naming-industry veteran and 24-year employee of Brand Institute, Inc. |
2021 |
|
Dec 22, 2021
FDA Approves TEZSPIRE™ (tezepelumab-ekko), AstraZeneca and Amgen's First-in-Class Treatment for Severe Asthma Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE™, the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients. |
|
Dec 21, 2021
EMA Approves NUVAXOVID®, Novavax's COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Novavax in naming their EMA-approved COVID-19 vaccine: NUVAXOVID®. |
|
Dec 19, 2021
Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 vaccine: SPIKEVAX®. |
|
Dec 13, 2021
FDA Approves Allergan's VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First Eye Drop Approved to Treat Age-Related Presbyopia in Adults Brand Institute is proud to announce its successful partnership with Allergan, Inc., an AbbVie company, in naming VUITY™, the first and only treatment approved by the U.S. Food & Drug Administration (FDA) to treat age-related blurry near vision (Presbyopia). |
|
Dec 10, 2021
FDA Issues Emergency Use Authorization For Astrazeneca's Evusheld™ (Tixagevimab Co-packaged With Cilgavimab), The First Antibody Therapy Authorized In The U.S. For Pre-exposure Prophylaxis Of COVID-19 Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the development of the nonproprietary names tixagevimab and cilgavimab, together denoting the first long-acting antibody combination authorized for emergency use by the U.S. Food and Drug Administration (FDA) for pre-exposure prevention of COVID-19. |
|
Dec 07, 2021 - Cision
MHRA Approves XEVUDY® (sotrovimab), GlaxoSmithKline and Vir Biotechnology's Monoclonal Antibody Treatment for Patients with COVID‑19 Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID–19 infection. |
|
Nov 24, 2021 - Cision
FDA Approves Takeda's Livtencity™ (maribavir), First Treatment Approved for Post-Transplant Cytomegalovirus (CMV) Infection Resistant to Other Drugs Brand Institute is proud to announce its successful partnership with Takeda Pharmaceuticals Company Limited in naming the first treatment approved by the US Food & Drug Administration (FDA) for adults and pediatric patients with post-transplant cytomegalovirus (CMV) infection that does not respond to available antiviral treatment for CMV. |
Oct 29, 2021 - ImaginAb
ImaginAb announces partnership with Brand Institute to develop a global brand name for CD8 ImmunoPET Technology ImaginAb Inc, a market-leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and radiopharmaceutical therapy (RPT), today announced it will be partnering with Miami-based branding agency, Brand Institute, on the development of a global brand name for ImaginAb’s CD8 ImmunoPET technology. |
|
Sep 20, 2021 - Cision
Health Canada Approves COVID-19 Vaccine Brand Names Comirnaty®, Spikevax® and Vaxzevria® for Pfizer/BioNTech, Moderna and AstraZeneca, Respectively Brand Institute is proud to announce its role in naming all three COVID-19 vaccine brand names recently approved by Health Canada: Comirnaty® (Pfizer/BioNTech), Spikevax® (Moderna), and Vaxzevria® (AstraZeneca). |
|
Aug 25, 2021 - Cision
FDA Approves COMIRNATY®, The First COVID-19 Vaccine Approved By The Agency And The First COVID-19 Vaccine Brand Name Approved In The U.S. Brand Institute is proud to announce its role in naming Pfizer and BioNTech's FDA-approved COVID-19 vaccine: COMIRNATY® (koe mir' na tee). |
|
Jul 22, 2021
Vaxzevria® Brand Naming Strategy and Logo Revealed Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is proud to share the official logo and creative naming strategy for AstraZeneca's COVID-19 vaccine: Vaxzevria® (vax zev' ree ah). |
2020 |
|
Dec 28, 2020
Introducing COMIRNATY®, the EU Brand Name forPfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute Brand Institute, the global leader in pharmaceutical and healthcare related name development, is proud to announce its role in naming Pfizer and BioNTech's COVID-19 vaccine: COMIRNATY® (koe mir' na tee). |
2022 |
|---|
|
May 04, 2022 FDA Approves Orphalan's CUVRIOR™ (trientine tetrahydrochloride), the first treatment for Wilson's disease in over five decades Brand Institute is proud to announce working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the United States Food and Drug Administration on April 28, 2022. |
|
Apr 18, 2022 FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed. |
|
Apr 25, 2022 FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc. Brand Institute is proud to announce working with Lipocine Inc. in developing the brand name TLANDO®, approved by the Food and Drug Administration (FDA) on March 28, 2022./span> |
|
Apr 19, 2022 Fernando González Díaz to Design Brand Institute's New Corporate Office in Puerto Rico As Brand Institute expands its operations in San Juan, Puerto Rico, it is proud to announce that it has enlisted Fernando González Díaz, Founder & Principal of Urban Venture Group (UVG), to design the company's new corporate office located at the Ritz-Carlton Reserve Dorado Beach Resort |
|
Apr 18, 2022 FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed. |
|
Mar 28, 2022 Oasmia announces completion of name change to Vivesto Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, announces that as of today, 28 March, its new name, Vivesto AB, has been registered with the Swedish Companies Registration Office. |
|
Feb 22, 2022 Maxim Biomedical's ClearDetect™ COVID-19 Antigen Home Test Receives Emergency Use Authorization (EUA) from the U.S. FDA Brand Institute is proud to announce its successful partnership with Maxim Biomedical (MaximBio) in naming their MaximBio ClearDetect™ COVID-19 Antigen Home Test. |
|
Feb 3, 2022 Carlos Beltrán Baseball Academy (CBBA) Partners with Global Naming Agency Brand Institute Brand Institute is proud to announce its support and enthusiastic patronage of the Carlos Beltrán Baseball Academy (CBBA), a prestigious high school in Florida, Puerto Rico, that specializes in teaching baseball, academics, and the personal development of their students. Its curriculum is singularly holistic, emphasizing both home runs and homework, pop flies and pop quizzes, batting averages and grade point averages—equally. |
|
Feb 1, 2022 FDA Approves SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Moderna in naming their FDA-approved COVID-19 vaccine: SPIKEVAX®, the second COVID-19 vaccine to be fully approved by the regulatory agency. |
|
Jan 24, 2022 Brand Institute Appoints William (Bill) Johnson to Co-Chief Executive Officer & President Brand Institute is pleased to announce the appointment of William (Bill) Johnson to the role of Co-Chief Executive Officer and President. Mr. Johnson is a naming-industry veteran and 24-year employee of Brand Institute, Inc. |
2021 |
|
Dec 22, 2021 FDA Approves TEZSPIRE™ (tezepelumab-ekko), AstraZeneca and Amgen's First-in-Class Treatment for Severe Asthma Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE™, the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients. |
|
Dec 21, 2021 EMA Approves NUVAXOVID®, Novavax's COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Novavax in naming their EMA-approved COVID-19 vaccine: NUVAXOVID®. |
|
Dec 19, 2021 Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 vaccine: SPIKEVAX®. |
|
Dec 13, 2021 FDA Approves Allergan's VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First Eye Drop Approved to Treat Age-Related Presbyopia in Adults Brand Institute is proud to announce its successful partnership with Allergan, Inc., an AbbVie company, in naming VUITY™, the first and only treatment approved by the U.S. Food & Drug Administration (FDA) to treat age-related blurry near vision (Presbyopia). |
|
Dec 10, 2021 FDA Issues Emergency Use Authorization For Astrazeneca's Evusheld™ (Tixagevimab Co-packaged With Cilgavimab), The First Antibody Therapy Authorized In The U.S. For Pre-exposure Prophylaxis Of COVID-19 Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the development of the nonproprietary names tixagevimab and cilgavimab, together denoting the first long-acting antibody combination authorized for emergency use by the U.S. Food and Drug Administration (FDA) for pre-exposure prevention of COVID-19. |
|
Dec 07, 2021 MHRA Approves XEVUDY® (sotrovimab), GlaxoSmithKline and Vir Biotechnology's Monoclonal Antibody Treatment for Patients with COVID‑19 Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID–19 infection. |
|
Nov 24, 2021 FDA Approves Takeda's Livtencity™ (maribavir), First Treatment Approved for Post-Transplant Cytomegalovirus (CMV) Infection Resistant to Other Drugs Brand Institute is proud to announce its successful partnership with Takeda Pharmaceuticals Company Limited in naming the first treatment approved by the US Food & Drug Administration (FDA) for adults and pediatric patients with post-transplant cytomegalovirus (CMV) infection that does not respond to available antiviral treatment for CMV. |
|
Oct 29, 2021 ImaginAb announces partnership with Brand Institute to develop a global brand name for CD8 ImmunoPET Technology ImaginAb Inc, a market-leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and radiopharmaceutical therapy (RPT), today announced it will be partnering with Miami-based branding agency, Brand Institute, on the development of a global brand name for ImaginAb’s CD8 ImmunoPET technology. |
|
Sep 20, 2021 Health Canada Approves COVID-19 Vaccine Brand Names Comirnaty®, Spikevax® and Vaxzevria® for Pfizer/BioNTech, Moderna and AstraZeneca, Respectively Brand Institute is proud to announce its role in naming all three COVID-19 vaccine brand names recently approved by Health Canada: Comirnaty® (Pfizer/BioNTech), Spikevax® (Moderna), and Vaxzevria® (AstraZeneca). |
|
Aug 25, 2021 FDA Approves COMIRNATY®, The First COVID-19 Vaccine Approved By The Agency And The First COVID-19 Vaccine Brand Name Approved In The U.S. Brand Institute is proud to announce its role in naming Pfizer and BioNTech's FDA-approved COVID-19 vaccine: COMIRNATY® (koe mir' na tee). |
|
Jul 22, 2021 Vaxzevria® Brand Naming Strategy and Logo Revealed Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is proud to share the official logo and creative naming strategy for AstraZeneca's COVID-19 vaccine: Vaxzevria® (vax zev' ree ah). |
2020 |
|
Dec 28, 2020 Introducing COMIRNATY®, the EU Brand Name forPfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute Brand Institute, the global leader in pharmaceutical and healthcare related name development, is proud to announce its role in naming Pfizer and BioNTech's COVID-19 vaccine: COMIRNATY® (koe mir' na tee). |